Deep Lens and Microsoft are focused on a groundbreaking approach to faster recruitment of the best-suited cancer patients to clinical trials. Deep Lens VIPER™, Deep Lens’ integrated cloud platform, is deployed at sites (cancer centers, IDNs, and community networks) to identify patients at the time of diagnosis by combining lab, EMR, and genomic data, and provide care teams with visibility and workflows to accelerate recruitment. VIPER dashboards are then available to sponsors with de-identified data to give those sponsors full visibility into the KPIs of patient screening at all participating sites, across all studies.

This insight improves transparency and accountability between site and sponsor, thereby helping to drive enrollment and compress study timelines to bring game-changing therapies to market sooner.

Industry Challenge:

The challenges facing clinical trial recruitment are multifaceted, and sponsors have been unable to determine where specific patients are in order to match them to studies. Clinical trial recruitment remains challenging with low participation and enrollment due to complex and siloed data, limited connectivity and interoperability, and ineffective manual tools for physicians and care teams. More than 15,000 oncology clinical trials are actively recruiting patients; yet estimates put the rate of participation as low as three percent of potential trial candidates. Identifying cancer patients who could benefit from a clinical trial is a time-consuming manual process today with hundreds of documents leading to inconsistencies in the screening, thereby leading to missed opportunities in the narrow window when patients could qualify for a trial.

Solution:

VIPER provides real-time visibility into trial site performance.

VIPER is a HIPAA-compliant public cloud service that accesses data “behind the firewall” at participating sites and automatically ingests data from pathology systems at the time of diagnosis, and from electronic medical records and genetic test results from top genetic testing labs globally. VIPER acts as an AI-driven screening platform for research coordinators and care teams, to find the best available clinical trials for a patients’ specific diagnosis—at the time of diagnosis. Through workflow integration, VIPER sends real-time notifications of a patient's eligibility for available clinical trials to the entire care team in the narrow enrollment window. Insight into this process at all sites via real-time interactive sponsor dashboards helps sponsors track key metrics and trial performance and enroll patients in a competitive environment.

VIPER™ for Biopharma & CROs

yayıncı: Deep Lens, Inc